Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia

Overview

Journal Glob J Health Sci

Specialties General Medicine
Public Health

Date 2015 Oct 24

PMID 26493428

Citations 10

Authors

Bijan Keikhaei

Homayon Yousefi

Mohammad Bahadoram

Affiliations

Soon will be listed here.

Abstract

Background & Aim: it is well known that hydroxyurea impacts on clinical and hematologic indices in sickle cell disease (SCD), we aimed to evaluate the effect of hydroxyurea on clinical and hematological improvement of sickle cell anemia.

Methods & Materials: In this cohort study 48 patients with sickle cell disease were enrolled and pain crisis, severity of pain, acute chest syndrome, the number of hospitalization, the rate of transfusion, spleen size, total Hb, HbF levels, MCV, MCH were compared before and after treatment with HU 10 mg/kg/day/for one year.

Results: In patients with Sickle cell disease Hu significantly decreased the rate of transfusion, hospitalization, spleen size and significantly increased Hb, RBC indices and HbF. Furthermore, we did not find any remarkable adverse effect related to HU during the one year follow up in patients.

Conclusion: We demonstrated that in the course of one year hydroxyurea 10 mg/kg/day can significantly increase HbF, total hemoglobin and RBC indices without any notable side effect in patients with SCD.

Citing Articles

Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment.

DAlessandro A, Nouraie S, Zhang Y, Cendali F, Gamboni F, Reisz J Haematologica. 2023; 108(12):3418-3432.

PMID: 37439373 PMC: 10690926. DOI: 10.3324/haematol.2023.283288.

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective.

Bou-Fakhredin R, De Franceschi L, Motta I, Cappellini M, Taher A Pharmaceuticals (Basel). 2022; 15(6).

PMID: 35745672 PMC: 9227505. DOI: 10.3390/ph15060753.

Revisiting fetal hemoglobin inducers in beta-hemoglobinopathies: a review of natural products, conventional and combinatorial therapies.

Mukherjee M, Rahaman M, Ray S, Shukla P, Dolai T, Chakravorty N Mol Biol Rep. 2021; 49(3):2359-2373.

PMID: 34822068 DOI: 10.1007/s11033-021-06977-8.

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Yasara N, Premawardhena A, Mettananda S Orphanet J Rare Dis. 2021; 16(1):114.

PMID: 33648529 PMC: 7919989. DOI: 10.1186/s13023-021-01757-w.

The relation between regular outpatient follow-up and frequency of emergency department visits in sickle cell pediatric patients.

Ismail A, Tarawah R, Azzouni Z, Alharbi L, Altayyar R Saudi Med J. 2020; 41(12):1324-1329.

PMID: 33294890 PMC: 7841586. DOI: 10.15537/smj.2020.12.05585.

References

Booth C, Inusa B, Obaro S . Infection in sickle cell disease: a review. Int J Infect Dis. 2009; 14(1):e2-e12. DOI: 10.1016/j.ijid.2009.03.010. View

Patel S, Purohit P, Mashon R, Dehury S, Meher S, Sahoo S . The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab--a single centre experience in eastern India. Pediatr Blood Cancer. 2014; 61(8):1341-6. DOI: 10.1002/pbc.25004. View

Patel D, Mashon R, Patel S, Das B, Purohit P, Bishwal S . Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin. 2012; 36(5):409-20. DOI: 10.3109/03630269.2012.709897. View

cokic V, Smith R, Beleslin-Cokic B, Njoroge J, Miller J, Gladwin M . Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003; 111(2):231-9. PMC: 151872. DOI: 10.1172/JCI16672. View

Lebensburger J, Pestina T, Ware R, Boyd K, Persons D . Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010; 95(9):1599-603. PMC: 2930964. DOI: 10.3324/haematol.2010.023325. View

Pack-Mabien A, Haynes Jr J . A primary care provider's guide to preventive and acute care management of adults and children with sickle cell disease. J Am Acad Nurse Pract. 2009; 21(5):250-7. DOI: 10.1111/j.1745-7599.2009.00401.x. View

Karimi M, Darzi H, Yavarian M . Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005; 27(7):380-5. DOI: 10.1097/01.mph.0000174386.13109.28. View

Zamani F, Shakeri R, Eslami S, Razavi S, Basi A . Hydroxyurea therapy in 49 patients with major beta-thalassemia. Arch Iran Med. 2009; 12(3):295-7. View

Segal J, Strouse J, Beach M, Haywood C, Witkop C, Park H . Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008; (165):1-95. PMC: 4781604. View

10.

Agrawal R, Patel R, Shah V, Nainiwal L, Trivedi B . Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014; 30(2):91-6. PMC: 4022916. DOI: 10.1007/s12288-013-0261-4. View

11.

Ghasemi A, Keikhaei B, Ghodsi R . Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia. Iran J Ped Hematol Oncol. 2014; 4(3):114-7. PMC: 4173031. View

12.

Green N, Barral S . Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res. 2013; 75(1-2):196-204. PMC: 3917141. DOI: 10.1038/pr.2013.227. View

13.

Bain B . Neonatal/newborn haemoglobinopathy screening in Europe and Africa. J Clin Pathol. 2008; 62(1):53-6. DOI: 10.1136/jcp.2008.060624. View

14.

Wong T, Brandow A, Lim W, Lottenberg R . Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014; 124(26):3850-7. PMC: 4271176. DOI: 10.1182/blood-2014-08-435768. View

15.

Keikhaei B, Mohseni A, Norouzirad R, Alinejadi M, Ghanbari S, Shiravi F . Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw. 2013; 24(1):45-52. DOI: 10.1684/ecn.2013.0328. View

16.

Inati A, Koussa S, Taher A, Perrine S . Sickle cell disease: new insights into pathophysiology and treatment. Pediatr Ann. 2008; 37(5):311-21. DOI: 10.3928/00904481-20080501-07. View

17.

Shahripour R, Mortazavi M, Barlinn K, Keikhaei B, Mousakhani H, Azarpazhooh M . Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?. J Stroke. 2014; 16(2):97-101. PMC: 4060272. DOI: 10.5853/jos.2014.16.2.97. View

18.

Green N, Barral S . Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatr Blood Cancer. 2010; 56(2):177-81. PMC: 3006002. DOI: 10.1002/pbc.22754. View

19.

Neves F, Menezes Neto O, Polis L, Bassi S, Brunetta D, Silva-Pinto A . Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment. Rev Bras Hematol Hemoter. 2013; 34(6):426-9. PMC: 3545429. DOI: 10.5581/1516-8484.20120107. View